Casi Pharmaceuticals Reports Q1 Earnings, Revenue Up 82%

Casi Pharmaceuticals reported Q1 EPS of 69 cents, up from (71) cents last year, and revenue of $6.2M, up from $3.4M last year. The company focused on advancing its lead program, CID-103, and dosed the initial patient in a Phase 1/2 study for chronic immune thrombocytopenia. They also worked to resolve the FDA clinical hold on their renal allograft antibody-mediated rejection program.

Tonix Pharmaceuticals Holding Corp (TNXP) reported its first quarter (Q1) 2025 financial results, with a net loss of $16.8 million, or $2.84 per share, compared to a net loss of $14.9 million, or $535.72 per share, in Q1 2024 [1]. The company reported net product revenue of $2.4 million, slightly below the estimated $2.55 million. Tonix Pharmaceuticals' cash position stood at $131.7 million as of March 31, 2025, providing sufficient liquidity to fund operations into Q2 2026. Research and Development (R&D) expenses decreased to $7.4 million, down from $12.9 million in Q1 2024, reflecting reduced clinical and manufacturing costs. The company's strategic focus on cost management is evident, as Selling, General, and Administrative (SG&A) expenses increased to $10.1 million from $9.3 million, while R&D expenses decreased significantly.

Lexicon Pharmaceuticals Inc (LXRX) also reported its Q1 2025 financial results, with a net loss of $25.3 million, or -$0.07 per share, compared to a net loss of $48.4 million, or -$0.10 per share, in Q1 2024 [2]. The company's revenue for the quarter was $1.3 million, slightly below the estimated $1.41 million. Lexicon Pharmaceuticals' strategic repositioning led to a significant decrease in total operating expenses, with SG&A expenses falling to $11.6 million from $32.1 million in the previous year. The company's cash and investments position stood at $194.8 million as of March 31, 2025. R&D expenses increased to $15.3 million, supporting ongoing Phase 2 and 3 clinical trials.

Both companies have shown a commitment to strategic cost management and R&D advancements. Tonix Pharmaceuticals' focus on reducing clinical and manufacturing costs, while Lexicon Pharmaceuticals' strategic repositioning has led to significant cost savings. However, both companies face challenges in meeting revenue expectations and sustaining their development efforts.

References:
[1] https://www.gurufocus.com/news/2855708/tonix-pharmaceuticals-q1-2025-earnings-eps-loss-of-284-beats-estimates-revenue-at-24-million-misses-expectations?mobile=true
[2] https://www.gurufocus.com/news/2859748/lexicon-pharmaceuticals-inc-lxrx-q1-2025-earnings-eps-beats-estimates-at-007-revenue-misses-at-13-million